# Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).

> **NCT02556229** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 20 (actual)

## Conditions studied

- Inflammatory Choroidal Neovascularization

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02556229
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556229, "Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02556229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*